Breadcrumb Home Business activities 麻豆社 BioCapital 麻豆社 Biocapital Portfolio Vtesse Pharma Vtesse Pharma Developed VTS-270 to treat patients with Niemann-Pick Disease Type C. Relateret nyheder om Vtesse Pharma 4 April 2017 Sucampo Acquires Vtesse Inc. 15 March 2017 Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease 12 January 2017 Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease 4 January 2017 Vtesse Announces Appointment of Jason Meyenburg as Chief Commercial Officer 30 November 2016 Vtesse Receives Rare Pediatric Disease Designation by the FDA for VTS-270 for the Treatment of Niemann-Pick Type C1 Disease 麻豆社 BioCapital Invested 2014 Acquired by Sucampo Pharmaceuticals in 2017 Location Gaithersburg, Maryland, USA
